US20080312575A1 - Haemofilters for Blood Detoxification - Google Patents
Haemofilters for Blood Detoxification Download PDFInfo
- Publication number
- US20080312575A1 US20080312575A1 US11/996,048 US99604806A US2008312575A1 US 20080312575 A1 US20080312575 A1 US 20080312575A1 US 99604806 A US99604806 A US 99604806A US 2008312575 A1 US2008312575 A1 US 2008312575A1
- Authority
- US
- United States
- Prior art keywords
- use according
- cyclodextrin
- blood
- cyclodextrins
- fabric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- PDORFGQZAPOTMC-WWXXEZNGSA-M C.C.COCC(O)COC.ClCC1CO1.OCC1C[C@H]2OCCCC[C@@H]1[C@@H](O)C2O.OCC1C[C@H]2OCCCC[C@@H]1[C@@H](O)C2O.O[Na] Chemical compound C.C.COCC(O)COC.ClCC1CO1.OCC1C[C@H]2OCCCC[C@@H]1[C@@H](O)C2O.OCC1C[C@H]2OCCCC[C@@H]1[C@@H](O)C2O.O[Na] PDORFGQZAPOTMC-WWXXEZNGSA-M 0.000 description 1
- NDWZZSXKQCARQB-IQCJOIPSSA-N CCC(C)(C)CC(C)(C)C(=O)OCC(CO)OC.CCC(C)(C)CC(C)(C)C(=O)OCC(O)COC.O.[2H]C.[2H]C Chemical compound CCC(C)(C)CC(C)(C)C(=O)OCC(CO)OC.CCC(C)(C)CC(C)(C)C(=O)OCC(O)COC.O.[2H]C.[2H]C NDWZZSXKQCARQB-IQCJOIPSSA-N 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/10—Supported membranes; Membrane supports
- B01D69/105—Support pretreatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
Definitions
- the present invention regards the use of supported cylcodextrins for the detoxification of the blood.
- the sepsis syndrome is a serious complication of the infection by gram-negative germs.
- this syndrome involves all organs and apparatuses, leading to multi-organ insufficiencies which require the applications of artificial aids (automatic respirator, artificial kidney, heart stimulators).
- artificial aids automated respirator, artificial kidney, heart stimulators.
- septic shock which can lead to death.
- Sepsis is triggered by the liberation of the exotoxins and endotoxins coming from the outer capsule of bacteria.
- Such substances are lipopolysaccharides which, upon entering into circulation, trigger a series of reactions involving the immune system in its humoral and cellular components.
- the situations most at-risk for this disease include: serious traumas perforations of intestines, upper abdominal surgery operations, especially in diabetic or immunodepressed elderly patients.
- the reaction of the organism to the endotoxins frequently causes a series of responses involving the microcirculation of the organs (septic cascade).
- Antibiotic therapy and the substitution of the damaged organs with artificial aids do not always succeed in stemming the septic cascade.
- the most effective treatment of sepsis is therefore the prevention of the invasion of the organism by the bacterial toxins, before these induce the septic cascade.
- LPS lipopolysaccharides
- hydrophobic lipid chain which is responsible for the toxic properties
- hydrophilic central polysaccharide chain and a hydrophilic O-polysaccharide side chain, which is specific for each bacterium strain.
- the lipopolysaccharides tend to form aggregates of various size, in particular micelles of about 1,000 KDa weight, in aqueous solvent. Consequently, these are not separable from the blood by means of ultrafiltration, since they do not pass through the pores of the membrane.
- hemofilters are available comprising antibiotics capable of detoxifying the blood. Nevertheless, such filters have an enormous cost.
- FIG. 1 shows the truncated cone structure of cyclodextrins
- FIG. 2 represents an example of the structure of ⁇ -cyclodextrin.
- the present invention regards the use of a hemofilter comprising a solid support to which cyclodextrins or cyclodextrin derivatives are covalently bonded.
- the solid supports employed in the invention can be polymeric resins obtained by means of a cross-linking reaction between the cyclodextrins and appropriate cross-linking agents, for example epichlorohydrin, isocyanates, polyamines, acrylates, carbonates; or fibre or fabric supports, for example cellulose, or non-woven fabric, for example polypropylene, to which the cyclodextrins are bonded by means of chemical or physical treatments such as the use of electron beam.
- the preferred are the natural cellulose supports.
- Another support preferably employed is silica, coated with polyethylenimines derivatised with cyclodextrins.
- the cyclodextrins also called cycloamyloses, cycloglucans, cyclomaltosides, are cyclic oligosaccharides constituted by the union, with ⁇ (1,4) bonds, of glucose units in a quantity which varies from 6 to 12.
- the word CD is preceded by a Greek letter which indicates the number of glucose units present in the ring (a corresponds to 6 units, ⁇ corresponds to 7 units, etc.).
- the cyclodextrins are the product of the enzymatic degradation of the amide, by the enzyme glycosiltransferase (CGTase) produced by different bacteria (examples: Bacillus macerans, Klebsiella pneumonite, Bacillua stearothermophilus, Bacillus megaterium etc.).
- CGTase glycosiltransferase
- the CGTase enzyme breaks the helical structure of the amide and causes the simultaneous formation of ⁇ (1,4) bonds between the glucose molecules, which lead to the obtainment of cyclic oligoglucosides.
- the cyclodextrins as shown in FIGS. 1 and 2 , have a truncated cone structure with the hydroxyl groups towards the outside and the carbon, hydrogen atoms and hetero-oxide bonds towards the inside of the structure. Moreover, the primary hydroxyl groups are positioned in the zone of the smaller-diameter truncated cone and the secondary hydroxyl groups in the greater-diameter truncated cone zone.
- This structure confers particular properties to the CDs: the high electron density, caused by the glycosidic oxygens, makes the cavity of the hydrophobic molecules apolar and confers a hydrophilic character to the exterior.
- the principle underlying the invention is therefore that of binding the water-soluble cyclodextrins to a solid support. Blood is passed over said support, in particular blood plasma.
- the hydrophobic inner cavity of the cyclodextrins holds the bacterial endotoxins and thus permits the detoxification of the blood which is then reinserted clean into circulation.
- the detoxification is possible in that the endotoxins or lipopolysaccharides are hydrophobic molecules and thus form a stable and reversible complex with the hydrophobic inner cavity of the cyclodextrins, called inclusion complex.
- the cyclodextrins preferably used are the alpha, beta, gamma cyclodextrin and their derivatives such as hydroxypropyls, sulphates and ethylsulfonates.
- the most preferred cyclodextrin is the alpha cyclodextrin.
- the synthesis of the solid polymeric support occurs by making the cyclodextrins react with appropriate cross-linking agents.
- Said cross-linking agents are advantageously bifunctional molecules having a functional group at the two ends capable of reacting with the primary and secondary hydroxyls of the cyclodextrins (for example epoxides and halides).
- cross-linking agents are epichlorohydrin, isocyanates, polyamines, acrylates, and carbonates; preferably epichlorohydrin is used.
- the synthesis method is known in literature, for example in the following article: E. Renard, G. Barnathan, A. Deratani and B. Sebille, “Characterization and structure of cyclodextrin-epichlorohydrin polymers-effects of synthesis parameters, (1996), Proceeding of the Eighth International Symposium on Cyclodextrins.
- the synthesised polymers are in granular form, insoluble in water and in most organic solvents (alcohol, chloroform, acetone, DMF, DMSO etc.).
- the polymers preferably used for the objects of the invention are polymers obtained from the cross-linking of cyclodextrins with epichlorohydrin, having cyclodextrin content in the range of 200-900 ⁇ mol/g, preferably 600-800 ⁇ mol/g.
- glycidyl methacrylate (GMA), acrylic acid, N-vinylpyrrolidones, acrylamides and vinyl acetate.
- the used monomer is glycidyl methacrylate.
- the GMA monomer is of particular interest due to the presence of an extremely reactive group, such as the epoxide.
- the functionalisation of the latter occurs with the cyclodextrin.
- the functionalisation methods with CDs of fabrics employed in the present invention are described in the literature, for example in the following articles: K. Poulakis, H. J. Buschmann and E. Schollmeyer, Patent DE 40 35378 A1, (1992); H. Reuscher and R. Hirsenkorn, EP 0 697 415 A1, (1995); H. Reuscher and R. Hirsenkorn, Patent DE 19 520 967, (1995); P. Le Thuaut, G. Crini, M. Morcellet, A. Naggi, U. Maschke, C. Vecchi, X. Coqueret, G. Torri and B. Martel, J. Appl. Polym. Sci., (1997).
- the present invention regards a method for the detoxification of the blood comprising the following steps:
- step d) the blood thus detoxified can be immediately transferred back to the patient.
- the invention regards the use of a hemofilter and detoxification method of the blood as described above, in the case of blood intoxication caused by the improper intake of several drug classes, for example barbiturates, or of other poisonous substances. These substance, like the lipopolysaccharides, form complexes with the supported cyclodextrins and hence are removed from the blood.
- the cyclodextrins can be polymerised by making one of the hydroxyl groups react with epichlorohydrin, bifunctional molecule.
- the epichlorohydrin can react with the CD (cross-linking reaction) and/or with itself (homopolymerisation), as shown in the reaction diagram 1, leading to the synthesis of the polymer shown in diagram 2.
- a mechanical stirrer mixes different percentages of cyclodextrin (Wacker) and NaOH (Carlo Erba) in aqueous solution.
- the desired amount of epichlorohydrin (Fluka) is slowly dripped, and the formation of a whitish paste of high viscosity is immediately observed, which is maintained under vigorous stirring for different times as described in table 1.
- acetone is added and the product is recovered for gooch filtration.
- the excess non-reacted epichlorohydrin and cyclodextrin is eliminated by means of washing of the polymer with hot water and ethanol (Girelli) in Soxhlet.
- the recovered product is dried by means of lyophilisation.
- the glucose obtained by a total hydrolysis of the polymers, is quantified with colourimetric metering (employing phenol).
- Glucose solution volume ( ⁇ l) Water volume ( ⁇ l) 0 500 20 480 30 470 40 460
- the calculation of the cyclodextrin content in the synthesised polymers has permitted dividing the materials into two groups: with low ( ⁇ 300 ⁇ mol/g) and high ( ⁇ 600/800 ⁇ mol/g) CD content.
- the fabrics are prepared according to the method described in “Grafting of cyclodextrins onto polypropylene nonwoven fabrics for the manufacture of reactive filters. II Characterization” B. Martel, P. Le Thuaut, G. Crini, M. Morcellet, A. Naggi, U. Maschke, S. Bertini, C. Vecchi, X. Coqueret, and G. Torri J. Appl. Polym. Sci., 78: 2166-2173, (2000) according to the diagram described in FIG. 3 .
- the non-woven fabric is physically activated by using 5-30 Mrad with an apparatus which provides a basic activation dose by 50 KGy (5 Mrad) electron beam; to obtain greater doses the irradiation is repeated.
- the grafting reaction of the glycidyl methacrylate occurs by immerging the activated fabric in an aqueous bath containing the monomer in concentration from 1-70%, and heating in inert atmosphere at 70° C. for times which vary from 20-200 minutes.
- the amount of bound GMA is calculated from the increase in weight of the fabric after extended washings and drying.
- the derivatisation with cyclodextrin occurs by immerging the functionalised fabric in a solution of cyclodextrin in DMF/H 2 O and heating to 80° C. for 8-24 h.
- cyclodextrins cross-linked with epichlorohydrin P1776: Gel beta CD; P1780: Gel gamma CD; P1793: Gel alpha CD
- silica coated with polyethylenimines derivatised with CD SiPEICD
- polypropylene support derivatised with beta cyclodextrin P1708
- the solutions are recovered by centrifugation at 5000 rpm for 5 minutes. From the supernatants, filtered on 1.6 ⁇ c glass fibre filters, different aliquots are drawn. The first (0.5 ml) is analysed with the phenol/sulphuric acid method, the second (5 ml) is lyophilised, and after having been taken up in 1.6 ml metered according to the Carbocyanine Dye Assay method.
- the reagent 1 is added to the reagent 3 in 1:2 ratio (w/vol); when solubilisation is completed, the reagent 2 is added in 1:4 (vol/vol) ratio, and finally the reagent 4 is added in 1:0.01 (vol/vol) ratio.
- the lyophilised aliquot is taken up in 0.4 ml of the reagent 2 and water is added up to a volume of 1 ml.
- the resins P1776, P1780, P1793 and P1708 were retested in aqueous LPS solution and in a 0.15M NaCl solution.
- 200 mg of P1793 was treated, compared with 100 mg of P1776 and P1780 left stirring with 5 ml of a (10 mg/L) LPS solution in distilled water for 2 hours.
- the solutions are recovered by centrifugation at 5000 rpm for 5 minutes. Two aliquots (500 ⁇ l) were metered of each with the phenol/sulphuric acid method described in example 1.
- cyclodextrins are compounds which can be easily and thus economically supplied.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Filtering Materials (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
- The present invention regards the use of supported cylcodextrins for the detoxification of the blood.
- The sepsis syndrome is a serious complication of the infection by gram-negative germs.
- Frequently, this syndrome involves all organs and apparatuses, leading to multi-organ insufficiencies which require the applications of artificial aids (automatic respirator, artificial kidney, heart stimulators). One particularly feared and widespread complication of sepsis is septic shock, which can lead to death.
- Sepsis is triggered by the liberation of the exotoxins and endotoxins coming from the outer capsule of bacteria. Such substances are lipopolysaccharides which, upon entering into circulation, trigger a series of reactions involving the immune system in its humoral and cellular components. The situations most at-risk for this disease include: serious traumas perforations of intestines, upper abdominal surgery operations, especially in diabetic or immunodepressed elderly patients.
- The reaction of the organism to the endotoxins frequently causes a series of responses involving the microcirculation of the organs (septic cascade).
- Such reaction, while considered a defense of the organism at the bacterial invasion, is often abnormal, inducing the production of numerous inflammation mediators (cytokines and other microproteins), responsible for the self-amplification process of the response, which causes serious damage to organs and apparatuses.
- Antibiotic therapy and the substitution of the damaged organs with artificial aids do not always succeed in stemming the septic cascade.
- The most effective treatment of sepsis is therefore the prevention of the invasion of the organism by the bacterial toxins, before these induce the septic cascade.
- The lipopolysaccharides (LPS) are characteristic components of the cellular membrane of the gram-negative bacteria; they are not present in gram-positive bacteria.
- These are molecules composed of a hydrophobic lipid chain, which is responsible for the toxic properties, a hydrophilic central polysaccharide chain and a hydrophilic O-polysaccharide side chain, which is specific for each bacterium strain.
- The lipopolysaccharides tend to form aggregates of various size, in particular micelles of about 1,000 KDa weight, in aqueous solvent. Consequently, these are not separable from the blood by means of ultrafiltration, since they do not pass through the pores of the membrane.
- Over the years, numerous blood detoxification techniques have been developed, which however have the disadvantage of not being very effective and requiring very high costs particularly due to the employed materials. For example, hemofilters are available comprising antibiotics capable of detoxifying the blood. Nevertheless, such filters have an enormous cost.
- The aforesaid problems are resolved by the use of a hemofilter as outlined in the attached claims.
- The invention will be explained in detail below with reference to the following figures:
-
FIG. 1 shows the truncated cone structure of cyclodextrins; -
FIG. 2 represents an example of the structure of β-cyclodextrin. - In a first aspect, the present invention regards the use of a hemofilter comprising a solid support to which cyclodextrins or cyclodextrin derivatives are covalently bonded.
- The solid supports employed in the invention can be polymeric resins obtained by means of a cross-linking reaction between the cyclodextrins and appropriate cross-linking agents, for example epichlorohydrin, isocyanates, polyamines, acrylates, carbonates; or fibre or fabric supports, for example cellulose, or non-woven fabric, for example polypropylene, to which the cyclodextrins are bonded by means of chemical or physical treatments such as the use of electron beam. Among these last, the preferred are the natural cellulose supports. Another support preferably employed is silica, coated with polyethylenimines derivatised with cyclodextrins.
- The cyclodextrins (CD), also called cycloamyloses, cycloglucans, cyclomaltosides, are cyclic oligosaccharides constituted by the union, with α(1,4) bonds, of glucose units in a quantity which varies from 6 to 12. The word CD is preceded by a Greek letter which indicates the number of glucose units present in the ring (a corresponds to 6 units, β corresponds to 7 units, etc.).
- The cyclodextrins are the product of the enzymatic degradation of the amide, by the enzyme glycosiltransferase (CGTase) produced by different bacteria (examples: Bacillus macerans, Klebsiella pneumonite, Bacillua stearothermophilus, Bacillus megaterium etc.).
- The CGTase enzyme breaks the helical structure of the amide and causes the simultaneous formation of α(1,4) bonds between the glucose molecules, which lead to the obtainment of cyclic oligoglucosides.
- The cyclodextrins, as shown in
FIGS. 1 and 2 , have a truncated cone structure with the hydroxyl groups towards the outside and the carbon, hydrogen atoms and hetero-oxide bonds towards the inside of the structure. Moreover, the primary hydroxyl groups are positioned in the zone of the smaller-diameter truncated cone and the secondary hydroxyl groups in the greater-diameter truncated cone zone. - This structure confers particular properties to the CDs: the high electron density, caused by the glycosidic oxygens, makes the cavity of the hydrophobic molecules apolar and confers a hydrophilic character to the exterior.
- The principle underlying the invention is therefore that of binding the water-soluble cyclodextrins to a solid support. Blood is passed over said support, in particular blood plasma. The hydrophobic inner cavity of the cyclodextrins holds the bacterial endotoxins and thus permits the detoxification of the blood which is then reinserted clean into circulation.
- The detoxification is possible in that the endotoxins or lipopolysaccharides are hydrophobic molecules and thus form a stable and reversible complex with the hydrophobic inner cavity of the cyclodextrins, called inclusion complex.
- In most cases the ratio between the CD and the hosted molecule is 1:1 and there are no covalent bonds, while equilibrium is established of associative-dissociative type, due mainly to Van der Waals interactions and hydrogen bonds between the included molecule and the hydroxyls of the CD.
- For the objects of the invention, the cyclodextrins preferably used are the alpha, beta, gamma cyclodextrin and their derivatives such as hydroxypropyls, sulphates and ethylsulfonates. The most preferred cyclodextrin is the alpha cyclodextrin.
- The synthesis of the solid polymeric support occurs by making the cyclodextrins react with appropriate cross-linking agents. Said cross-linking agents are advantageously bifunctional molecules having a functional group at the two ends capable of reacting with the primary and secondary hydroxyls of the cyclodextrins (for example epoxides and halides).
- Examples of cross-linking agents are epichlorohydrin, isocyanates, polyamines, acrylates, and carbonates; preferably epichlorohydrin is used. The synthesis method is known in literature, for example in the following article: E. Renard, G. Barnathan, A. Deratani and B. Sebille, “Characterization and structure of cyclodextrin-epichlorohydrin polymers-effects of synthesis parameters, (1996), Proceeding of the Eighth International Symposium on Cyclodextrins.
- The synthesised polymers are in granular form, insoluble in water and in most organic solvents (alcohol, chloroform, acetone, DMF, DMSO etc.).
- The polymers preferably used for the objects of the invention are polymers obtained from the cross-linking of cyclodextrins with epichlorohydrin, having cyclodextrin content in the range of 200-900 μmol/g, preferably 600-800 μmol/g.
- The grafting of the cyclodextrins on yarn or fabric, for example cellulose, or on non-woven fabric in polymeric material, for example cellulose acetate, polypropylene, polyethylene or polyester, occurs by interposing a linker monomer between the substrate and the cyclodextrins.
- There are different monomers which can be employed in the grafting reaction, for example glycidyl methacrylate (GMA), acrylic acid, N-vinylpyrrolidones, acrylamides and vinyl acetate. Preferably, the used monomer is glycidyl methacrylate.
- The GMA monomer is of particular interest due to the presence of an extremely reactive group, such as the epoxide.
- The method employed for the grafting of the monomer on the substrate is described in the literature, for example in the following articles: P. Le Thuaut, G. Crini, M. Morcellet, A. Naggi, U. Maschke, C. Vecchi, X. Coqueret, G. Torri and B. Martel, J. Appl. Polym. Sci., (1997); P. Le Thuaut, Macromolecular and Organic Chemistry Doctoral thesis, University of Science and Technology of Lille, Macromolecular and Chemistry Laboratory, “Fonctionnalisation de supports textiles pour l'elaboration de filtres adsorbeurs de polluants organiques”, (2000). The synthesis typically comprises the following steps:
-
- Activation of the solid substrate by means of chemical or physical treatment, for example with electron beam etc. The preferred technique is the irradiation with electron beam;
- Radical grafting reaction of the monomer which leads both to the derivatisation of the substrate and the monomer polymerisation, generating spacers of different length.
- Once the spacer is grafted on the substrate, the functionalisation of the latter occurs with the cyclodextrin. The functionalisation methods with CDs of fabrics employed in the present invention are described in the literature, for example in the following articles: K. Poulakis, H. J. Buschmann and E. Schollmeyer, Patent DE 40 35378 A1, (1992); H. Reuscher and R. Hirsenkorn, EP 0 697 415 A1, (1995); H. Reuscher and R. Hirsenkorn, Patent DE 19 520 967, (1995); P. Le Thuaut, G. Crini, M. Morcellet, A. Naggi, U. Maschke, C. Vecchi, X. Coqueret, G. Torri and B. Martel, J. Appl. Polym. Sci., (1997). In a second aspect, the present invention regards a method for the detoxification of the blood comprising the following steps:
-
- a) Drawing the blood from a patient at risk of sepsis;
- b) Separating the plasma from the remaining part of the blood, inserting, on the arterial line of the extracorporeal circuit, a plasma filter of polysulfone or its derivatives, for example polyethersulfone;
- c) Filtering the plasma on the hemofilter according to the invention;
- d) Reuniting the filtered plasma with the previously separated blood part.
- Once step d) has been concluded, the blood thus detoxified can be immediately transferred back to the patient.
- In a third aspect, the invention regards the use of a hemofilter and detoxification method of the blood as described above, in the case of blood intoxication caused by the improper intake of several drug classes, for example barbiturates, or of other poisonous substances. These substance, like the lipopolysaccharides, form complexes with the supported cyclodextrins and hence are removed from the blood.
- The cyclodextrins can be polymerised by making one of the hydroxyl groups react with epichlorohydrin, bifunctional molecule. In a basic environment, the epichlorohydrin can react with the CD (cross-linking reaction) and/or with itself (homopolymerisation), as shown in the reaction diagram 1, leading to the synthesis of the polymer shown in diagram 2.
- In a thermostatic reactor, a mechanical stirrer mixes different percentages of cyclodextrin (Wacker) and NaOH (Carlo Erba) in aqueous solution. After an hour of stirring, the desired amount of epichlorohydrin (Fluka) is slowly dripped, and the formation of a whitish paste of high viscosity is immediately observed, which is maintained under vigorous stirring for different times as described in table 1. Then, acetone (Acros) is added and the product is recovered for gooch filtration. The excess non-reacted epichlorohydrin and cyclodextrin is eliminated by means of washing of the polymer with hot water and ethanol (Girelli) in Soxhlet. Finally, the recovered product is dried by means of lyophilisation.
- For the determination of the CD present in the synthesis products, the glucose, obtained by a total hydrolysis of the polymers, is quantified with colourimetric metering (employing phenol).
- To such end, 20 mg of polymer is suspended in 5 ml of 1 M trifluoroacetic acid (Fluka), the suspension is heated at 120° C. for eight hours under vigorous stirring. After which, the solution is evaporated to eliminate the trifluoroacetic acid. The product is recovered in 10 ml of distilled water. The glucose content is determined by means of colourimetric metering with phenol and sulphuric acid. The method requires a calibration line: to such end, solutions are prepared with difference glucose concentration (Fluka) as shown in the table, beginning with a mother solution of 1% glucose by weight (1 g/l).
-
Glucose solution volume (μl) Water volume (μl) 0 500 20 480 30 470 40 460 - The same procedure is repeated for the hydrolysed polymer solution. In fact, different volumes are drawn from the 10 ml neutral solutions, diluted with different quantities of water as reported in the table:
-
Volume glucose solution to be metered (μl) Water volume (μl) 20 480 50 450 100 400 - To these solutions, placed in test tubes, 0.5 ml of a 5% by weight aqueous phenol solution (Carlo Erba) is added. After 10 minutes, 2.5 ml of 98% H2SO4 is added (Carlo Erba), vigorously stirring. After another ten minutes after this addition, the absorbance is read at the wavelength of 480 nm. Using the Lambert-Beer law, it is possible to build the calibration line and therefore determine the glucose content in the hydrolysed polymer solution. In this manner the cyclodextrin content is obtained, expressed as μmoles or μg per g of material.
- The calculation of the cyclodextrin content in the synthesised polymers has permitted dividing the materials into two groups: with low (˜300 μmol/g) and high (˜600/800 μmol/g) CD content.
- The different experimental conditions and the obtained CD values are reported in table 1.
-
TABLE 1 Description of the obtained polymers Epi./CD CD (molar NaOH Vol Time T % CD Sample (g.) ratio) (23% w/w) (h) (° C.) (w/w) μmol/g Beta-20 3 20/1 80 ml 24 80 20 176 Beta-57 3 20/1 4 ml 5 50 57 502 Beta-60 3 20/1 4 ml 2 50 60 527 Beta-70 3 20/1 3 ml 5 50 70 617 Beta-80 3 60/1 3 ml 24 50 80 705 Beta-84 350 20/1 500 ml 24 50 84 740 Gamma-73 350 15/1 150 ml 4 50 73 562 (50% w/w) Alpha-31 350 15/1 150 ml 2 50 31 319 (50% w/w) - The material, indicated in the table as beta-20, was synthesised by using the method known in literature (E. Renard, G. Barnathan, A. Deratani and B. Sebille, “Characterization and structure of cyclodextrin-epichlorohydrin polymers-effects of synthesis parameters, (1996), Proceeding of the Eighth International Symposium on Cyclodextrins).
- During both the characterisation and calculation studies of the complexing capacities, this material was taken as reference.
- From an analysis of the experimental conditions employed for the synthesis, it is concluded that the fundamental parameter for the obtainment of high cyclodextrin content materials is the quantity of solvent present in the reaction mixture.
- Synthesis of the Solid Supports in Fabric and Non-Woven Fabric.
- The fabrics are prepared according to the method described in “Grafting of cyclodextrins onto polypropylene nonwoven fabrics for the manufacture of reactive filters. II Characterization” B. Martel, P. Le Thuaut, G. Crini, M. Morcellet, A. Naggi, U. Maschke, S. Bertini, C. Vecchi, X. Coqueret, and G. Torri J. Appl. Polym. Sci., 78: 2166-2173, (2000) according to the diagram described in
FIG. 3 . The non-woven fabric is physically activated by using 5-30 Mrad with an apparatus which provides a basic activation dose by 50 KGy (5 Mrad) electron beam; to obtain greater doses the irradiation is repeated. The grafting reaction of the glycidyl methacrylate occurs by immerging the activated fabric in an aqueous bath containing the monomer in concentration from 1-70%, and heating in inert atmosphere at 70° C. for times which vary from 20-200 minutes. The amount of bound GMA is calculated from the increase in weight of the fabric after extended washings and drying. The derivatisation with cyclodextrin occurs by immerging the functionalised fabric in a solution of cyclodextrin in DMF/H2O and heating to 80° C. for 8-24 h. The quantity of cyclodextrin introduced in calculated from the increase in weight of the fabric after extended washings and drying. - Examples of Biological Activity of the Supported Cyclodextrins of the Invention.
- The following material types were tested: cyclodextrins cross-linked with epichlorohydrin (P1776: Gel beta CD; P1780: Gel gamma CD; P1793: Gel alpha CD), silica coated with polyethylenimines derivatised with CD (SiPEICD), polypropylene support derivatised with beta cyclodextrin (P1708).
- 100 mg of each material containing rehydrated and washed CD, is left stirring with 5 ml of a (10 mg/L) LPS solution in distilled water for 2 ore. 222 mg of P1708 are left stirring, for two hours, with 3 ml of solution.
- The solutions are recovered by centrifugation at 5000 rpm for 5 minutes. From the supernatants, filtered on 1.6 μc glass fibre filters, different aliquots are drawn. The first (0.5 ml) is analysed with the phenol/sulphuric acid method, the second (5 ml) is lyophilised, and after having been taken up in 1.6 ml metered according to the Carbocyanine Dye Assay method.
- Phenol/Sulphuric Acid Method
- To the sample aliquots (500 μl), added to 5001 of 5% phenol in water, 2 ml of concentrated sulphuric acid is added; after 20 minutes of incubation, upon delicate stirring the absorbance is read at a wavelength of 480 nm.
- Carbocyanine Dye Assay Method
- 2) pH4 0.03 M Na-acetate buffer
3) 1,4-dioxane: pH4 0.03 M Na-acetate buffer (1:1 vol/vol)
4) 0.01 M Ascorbic acid - To prepare the dye solution, the reagent 1 is added to the
reagent 3 in 1:2 ratio (w/vol); when solubilisation is completed, thereagent 2 is added in 1:4 (vol/vol) ratio, and finally the reagent 4 is added in 1:0.01 (vol/vol) ratio. - For the assay, the lyophilised aliquot is taken up in 0.4 ml of the
reagent 2 and water is added up to a volume of 1 ml. - After stirring, 0.6 ml of dye solution is added, and it is left in incubation at room temperature for 5 minutes. The reading of the absorbance is carried out at the wavelength of 460 nm (Johnson K. G. “Isolation and purification of lipopolysaccharides” in “Methods in carbohydrate chemistry” edited by BeMiller J. N. Whistler R. L. Shaw D. H.).
- As a comparison, samples of material obtained in analogous conditions are tested in the same conditions, but without the derivatisation with cyclodextrins (P1458; SiPEI;). In table 2 the retained LPS data is reported.
-
TABLE 2 CD μmol/g % retained LPS (% w/w Carbo- retained L CD) Phenol cyanine μg/CD μmol RESINS P1458 cross-linked 0 0 0 CMC (white) P1793 cross-linked 319 (31) 29 0.114 alphaCD P1776: cross-linked 740 (84) 8 0.027 betaCD P1780: cross-linked 562 (73) 52 0.231 gammaCD SiPEI: resin (white) 0 39 SiPEI CD: betaCD 32 (7) 60 6.450 resin FILTERS P1708 176 (25) 60 0.465 polypropylene/ GMA/betaCD indicates data missing or illegible when filed - Based on the obtained results, the resins P1776, P1780, P1793 and P1708 were retested in aqueous LPS solution and in a 0.15M NaCl solution. In this case, 200 mg of P1793 was treated, compared with 100 mg of P1776 and P1780 left stirring with 5 ml of a (10 mg/L) LPS solution in distilled water for 2 hours.
- Regarding P1708, 228 mg were weighed and left stirring with 3 ml of 50 μg/ml LPS in 0.15 M NaCl for 2 hours.
- Also in this case, the solutions are recovered by centrifugation at 5000 rpm for 5 minutes. Two aliquots (500 μl) were metered of each with the phenol/sulphuric acid method described in example 1.
-
TABLE 3 (solution in 0.15M NaCl) % μmol/g retained CD (% LPS Retained LPS w/w CD) Phenol μg/CD μmol RESINS P1793: cross-linked 319 51 0.235 alphaCD (31) P1776: cross-linked 740 46 0.189 betaCD (84) P1780: cross-linked 562 42 0.231 gammaCD (73) FILTERS P1708 polypropylene/ 176 20 0.074 GMA/betaCD (25) - The materials based on cyclodextrin cross-linked with epichlorohydrin have shown good absorption values and it may be assumed that there was no contribution from the crosslink of the cross-linking agent, given by the lack of absorption capacity shown by the cross-linked white CMC (P1458). The following absorption capacity scale was observed: beta<gamma<alpha, CD quantities in the material being equal. An analogous result was observed in the presence of ionic force.
- 200 mg of resin P1793 was left to rehydrate overnight and then washed with 300 ml of H2O in column. 20 ml of the 10 μg/ml LPS solution was passed through the resin, and 3 ml (experiment I) and 1 ml (experiment II) portions were collected. Each portion was lyophilised and metered in the presence of Carbocyanine as described in example 1. In tables 4 and 5 the concentrations of LPS in μg/ml in each portion are respectively reported for the first and second experiment. An initial effectiveness of the column and its progressive saturation is noted.
-
TABLE 4 Portion LPS (μg/ml) 1 3 2 2 3 6 4 7 -
TABLE 5 Portion LPS (μg/ml) 0 2 1 6 2 2 3 3 4 0 5 2 6 2 7 4 8 3 9 4 10 6 11 3 12 5 13 3 14 4 15 4 16 2 17 3 18 4 19 3 - 790 mg of P1780 resin was packed in the HPLC column, washed and rehydrated with distilled H2O for 5 hours. 5 ml of the 20 μg/ml LPS solution was passed through the resin in continuous recirculation for 30 minutes, and then an aliquot (500 μl; solution 2) was metered in double dosage, with the phenol/sulphuric acid method described in experiment method 1. For comparison, an aliquot was also metered of the LPS solution before the recirculation (solution 1). In table 6 the metered LPS concentrations in μg/ml are reported. The 60% absorption of the LPS is shown.
-
TABLE 6 Solution LPS (μg/ml) 1 24 2 14.51 - The same solutions were tested with the LAL-test method (CAMBREX). “Optimal” dilutions were prepared to take advantage of the sensitivity threshold of the method, foreseen at 0.125 EU/mL. The results are reported in table 7.
-
TABLE 7 Sol. 1 Sol. 2 start Column Dilution 20 mg/L LPS gammaCD - End 1:50000 Positive Positive LAL- LAL-test test 1:100000 Positive LAL-test +/− LAL-test 1:200000 Positive Negative LAL- LAL-test test 1:400000 LAL-test +/− LAL-test negative - Observations: the comparison between the two preparations shows a different positive result with the test for two proportional dilutions; it may therefore be hypothesised that in the sample treated with gamma-CD there was a removal of LPS equal to about 60%.
- The use of supported cyclodextrins for the production of a hemofilter for the selective removal of the lipopolysaccharides from the blood permits considerably reducing the cost of the single hemofilter, to the great advantage of the health of persons affected by sepsis: cyclodextrins are compounds which can be easily and thus economically supplied.
- Moreover, the effectiveness of detoxification of the blood is much greater than that of other currently-available filters.
- The use of supported cyclodextrins permits carrying out a single filtration of the plasma in order to obtain a complete elimination of the endotoxins, unlike the detoxifying systems of the prior art which require repeated applications to reach the same result.
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP054255561.7 | 2005-07-28 | ||
EP05425561A EP1752171A1 (en) | 2005-07-28 | 2005-07-28 | Haemofilters for blood detoxification |
PCT/IT2006/000583 WO2007013122A1 (en) | 2005-07-28 | 2006-07-27 | Haemofilters for blood detoxification |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080312575A1 true US20080312575A1 (en) | 2008-12-18 |
Family
ID=35116011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/996,048 Abandoned US20080312575A1 (en) | 2005-07-28 | 2006-07-27 | Haemofilters for Blood Detoxification |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080312575A1 (en) |
EP (1) | EP1752171A1 (en) |
JP (1) | JP2009502905A (en) |
CN (1) | CN101247841A (en) |
AU (1) | AU2006273606A1 (en) |
WO (1) | WO2007013122A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010012282A1 (en) * | 2010-03-22 | 2011-09-22 | Fresenius Medical Care Deutschland Gmbh | Pharmaceutical composition containing cyclodextrin copolymer |
US9505850B2 (en) | 2012-05-30 | 2016-11-29 | National University Corporation Kumamoto University | Endotoxin adsorbent |
US10625241B2 (en) * | 2017-06-22 | 2020-04-21 | B. Braun Avitum Ag | Hemocompatible adsorber for the dialysis of protein-bound uremic toxins |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011256111A (en) * | 2008-10-03 | 2011-12-22 | Hayashibara Biochem Lab Inc | Prophylactic and therapeutic agent for sepsis |
JP2011207917A (en) * | 2010-03-26 | 2011-10-20 | Aomori Prefectural Industrial Technology Research Center | Cyclodextrin polymer-containing composite material and method for producing the same |
CN107496441B (en) * | 2017-09-18 | 2021-10-29 | 山东大学 | Use of cyclodextrins for the treatment and/or prevention of sepsis |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5183809A (en) * | 1990-02-15 | 1993-02-02 | The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation | Cyclodextrin polymers and cyclodextrins immobilized on a solid surface |
US5516766A (en) * | 1990-02-15 | 1996-05-14 | The Trustees Of The University Of Pennsylvania | Cyclodextrin polymers and cyclodextrins immobilized on a solid surface |
US6613703B1 (en) * | 2000-04-27 | 2003-09-02 | Kimberly-Clark Worldwide, Inc. | Thermoplastic nonwoven web chemically reacted with a cyclodextrin compound |
US6689378B1 (en) * | 1999-12-28 | 2004-02-10 | Kimberly-Clark Worldwide, Inc. | Cyclodextrins covalently bound to polysaccharides |
US20050101581A1 (en) * | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
US20060030027A1 (en) * | 2004-08-04 | 2006-02-09 | Aspira Biosystems, Inc. | Capture and removal of biomolecules from body fluids using partial molecular imprints |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2116431A1 (en) * | 1991-09-06 | 1993-03-18 | Gurcharn S. Sidhu | Composition and method for reducing cholesterol concentration |
-
2005
- 2005-07-28 EP EP05425561A patent/EP1752171A1/en not_active Withdrawn
-
2006
- 2006-07-27 US US11/996,048 patent/US20080312575A1/en not_active Abandoned
- 2006-07-27 WO PCT/IT2006/000583 patent/WO2007013122A1/en active Application Filing
- 2006-07-27 AU AU2006273606A patent/AU2006273606A1/en not_active Abandoned
- 2006-07-27 CN CNA2006800275987A patent/CN101247841A/en active Pending
- 2006-07-27 JP JP2008523549A patent/JP2009502905A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5183809A (en) * | 1990-02-15 | 1993-02-02 | The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation | Cyclodextrin polymers and cyclodextrins immobilized on a solid surface |
US5516766A (en) * | 1990-02-15 | 1996-05-14 | The Trustees Of The University Of Pennsylvania | Cyclodextrin polymers and cyclodextrins immobilized on a solid surface |
US6689378B1 (en) * | 1999-12-28 | 2004-02-10 | Kimberly-Clark Worldwide, Inc. | Cyclodextrins covalently bound to polysaccharides |
US6613703B1 (en) * | 2000-04-27 | 2003-09-02 | Kimberly-Clark Worldwide, Inc. | Thermoplastic nonwoven web chemically reacted with a cyclodextrin compound |
US20050101581A1 (en) * | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
US20060030027A1 (en) * | 2004-08-04 | 2006-02-09 | Aspira Biosystems, Inc. | Capture and removal of biomolecules from body fluids using partial molecular imprints |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010012282A1 (en) * | 2010-03-22 | 2011-09-22 | Fresenius Medical Care Deutschland Gmbh | Pharmaceutical composition containing cyclodextrin copolymer |
US9505850B2 (en) | 2012-05-30 | 2016-11-29 | National University Corporation Kumamoto University | Endotoxin adsorbent |
US10155217B2 (en) | 2012-05-30 | 2018-12-18 | National University Corporation Kumamoto | Endotoxin adsorbent |
US10625241B2 (en) * | 2017-06-22 | 2020-04-21 | B. Braun Avitum Ag | Hemocompatible adsorber for the dialysis of protein-bound uremic toxins |
Also Published As
Publication number | Publication date |
---|---|
WO2007013122A1 (en) | 2007-02-01 |
EP1752171A1 (en) | 2007-02-14 |
WO2007013122A8 (en) | 2007-07-05 |
JP2009502905A (en) | 2009-01-29 |
AU2006273606A1 (en) | 2007-02-01 |
CN101247841A (en) | 2008-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6290840B2 (en) | Novel heparin and its utilization | |
US20080312575A1 (en) | Haemofilters for Blood Detoxification | |
CN101531740B (en) | Method for forming simulated cell outer layer membrane structure on surface of cross-linked chitosan | |
US4308377A (en) | Shaped material comprising denatured chitin and process for preparing same | |
JP6424343B2 (en) | Endotoxin adsorbent | |
CN102421803A (en) | Method for purifying glucose polymers for peritoneal dialysis solutions | |
US10155217B2 (en) | Endotoxin adsorbent | |
US9504707B2 (en) | Use of the modified polysaccharides for heparin neutralization | |
JP7462901B2 (en) | Endotoxin adsorbent and method for producing same | |
CN112876722A (en) | Traditional Chinese medicine coating for improving surface biocompatibility of medical instrument and preparation method thereof | |
Bayramgil | Grafting of Hydrophilic Monomers Onto Cellulosic Polymers for Medical | |
JPS5941647B2 (en) | Method for producing anticoagulant regenerated cellulose | |
JP4957886B2 (en) | Column with immune activation ability | |
EP2300062B1 (en) | Use of crosslinked chitosan polymer for heparin removal | |
Shajahan et al. | Chitosan: A versatile biomaterial for the 21st century | |
EP2396008A1 (en) | Use of a chitosan polymer for heparin neutralization | |
WO1994003269A1 (en) | Microspheres of polyhydroxylic materials | |
Santoso et al. | Citric Acid-Polyurethane-Chitosan-Based Innovative Biocomposites as Candidates of Antibacterial Dialyzer Membrane | |
Demirel | Studies towards the preparation of functionalized cellulose microspheres with affinities towards negatively charged biomembranes | |
Abakan | Synthesis and Characterization of PVA/CMC Cryogels as Ciprofloxacin Carries | |
Jayani et al. | Bacterial cellulose dissolution for high-value nano fibre application. | |
Ignacimuthua | Chitosan: A Versatile Biomaterial for the 21st Century | |
Reesh | Glucose Responsive Hydrogels: Synthesis and Investigation of the Biomedical Applications | |
CN111154010A (en) | Medical cationic polymer biopolymer material, preparation method and application | |
CN115463249A (en) | Platelet-rich plasma-loaded hydrogel and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: "ISTITUTO DI RICERCHE CHIMICHE E BIOCHIMICHE GIULI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRAZIANI, GIORGIO;NAGGI, ANNAMARIA;TORRI, GIANGIACOMO;REEL/FRAME:021115/0611 Effective date: 20080421 Owner name: HUMANITAS MIRASOLE S.P.A, ITALY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRAZIANI, GIORGIO;NAGGI, ANNAMARIA;TORRI, GIANGIACOMO;REEL/FRAME:021115/0611 Effective date: 20080421 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |